Skip to main content

Partnerships: Industry & Academic

Engaging Industry and Academic Partners

CCTG is know for cancer clinical trial research and is the world's largest cooperative collaborative oncology group. Our success is realized through our network of investigators who develop scientifically important and meaningful trials, conducted both rapidly and to rigorous standards. With over 40 years of experience there is no network that rivals the depth and breadth of operations with a global reputation for rapid execution of quality clinical trials.

Partnerships

National and international collaboration

Industry partnerships

While CCTG trials are independently conducted, analyzed and reported. Pharmaceutical or academic drug manufacturers provide CCTG access to their investigational new drugs because they recognize the high quality research being conducted through the group.

CCTG Partnerships quote

CX5 | SHAPE trial demonstrates that reduced radicality of surgical intervention can improve quality of life for patients

New study results show that simple hysterectomy is a safe option for women with early-stage, low-risk cervical cancer

A simple hysterectomy with pelvic node dissection is a safe treatment option for women with low-risk early-stage cervical cancer and may help improve quality of life, according to results from the CX5/SHAPE study, an international phase III clinical trial led by the Canadian Cancer Trials Group.

More >>
 
The Innovative Cancer Treatments of Tomorrow are Born Through Collaboration

The Innovative Cancer Treatments of Tomorrow are Born Through Collaboration

​Annette Hay, Senior Investigator and Co-PI of ExCELLirate Canada, the CCTG-co-Led national platform for exploring the promising applications of cell therapy research across a wide variety of cancers and other illnesses was recently featured as a signature initiative at Queen’s University.

More >>
 
Ensuring ongoing access to impactful clinical trials for Canadians

Successful $30 million Canadian Cancer Society grant renewal for the Canadian Cancer Trials Group

The Canadian Cancer Society (CCS) has renewed its support of the Canadian Cancer Trials Group (CCTG) with a five-year 30-million-dollar commitment to the national research network. The grant renewal represents a continuation of CCS’s largest research investment, which began in 1980 when they helped create the Canadian academic research group.

More >>
 
The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer

Funding announced for clinical trial that aims to improve the outcomes for patients with colorectal cancer after surgery

The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer, has been awarded $1,426,724 from the Canadian Institutes of Health Research (CIHR) Spring Project Competition.

More >>